These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32049643)

  • 1. Small-molecule modulation of p53 protein-protein interactions.
    Kuusk A; Boyd H; Chen H; Ottmann C
    Biol Chem; 2020 Jul; 401(8):921-931. PubMed ID: 32049643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterizing the protein-protein interaction between MDM2 and 14-3-3σ; proof of concept for small molecule stabilization.
    Ward JA; Romartinez-Alonso B; Kay DF; Bellamy-Carter J; Thurairajah B; Basran J; Kwon H; Leney AC; Macip S; Roversi P; Muskett FW; Doveston RG
    J Biol Chem; 2024 Feb; 300(2):105651. PubMed ID: 38237679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule stabilization of the p53 - 14-3-3 protein-protein interaction.
    Doveston RG; Kuusk A; Andrei SA; Leysen S; Cao Q; Castaldi MP; Hendricks A; Brunsveld L; Chen H; Boyd H; Ottmann C
    FEBS Lett; 2017 Aug; 591(16):2449-2457. PubMed ID: 28640363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein-protein interactions identifies a novel putative Mdm2-binding site in p53.
    Wong JH; Alfatah M; Sin MF; Sim HM; Verma CS; Lane DP; Arumugam P
    BMC Biol; 2017 Nov; 15(1):108. PubMed ID: 29121928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule inhibitors of the p53-MDM2.
    Hu CQ; Hu YZ
    Curr Med Chem; 2008; 15(17):1720-30. PubMed ID: 18673221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CARPs enhance p53 turnover by degrading 14-3-3sigma and stabilizing MDM2.
    Yang W; Dicker DT; Chen J; El-Deiry WS
    Cell Cycle; 2008 Mar; 7(5):670-82. PubMed ID: 18382127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fluorescent two-hybrid assay to screen for protein-protein interaction inhibitors in live cells: targeting the interaction of p53 with Mdm2 and Mdm4.
    Yurlova L; Derks M; Buchfellner A; Hickson I; Janssen M; Morrison D; Stansfield I; Brown CJ; Ghadessy FJ; Lane DP; Rothbauer U; Zolghadr K; Krausz E
    J Biomol Screen; 2014 Apr; 19(4):516-25. PubMed ID: 24476585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
    Sirous H; Chemi G; Campiani G; Brogi S
    Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patented inhibitors of p53-Mdm2 interaction (2006 - 2008).
    Weber L
    Expert Opin Ther Pat; 2010 Feb; 20(2):179-91. PubMed ID: 20100001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors.
    Kannan S; Partridge AW; Lane DP; Verma CS
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-molecule inhibitors of the p53-MDM2 interaction.
    Vu BT; Vassilev L
    Curr Top Microbiol Immunol; 2011; 348():151-72. PubMed ID: 21046355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules.
    Lauria A; Tutone M; Ippolito M; Pantano L; Almerico AM
    Curr Med Chem; 2010; 17(28):3142-54. PubMed ID: 20666726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.
    Liu Y; Wang X; Wang G; Yang Y; Yuan Y; Ouyang L
    Eur J Med Chem; 2019 Aug; 176():92-104. PubMed ID: 31100649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic Proteins Potently and Selectively Bind the Oncoprotein Gankyrin, Modulate Its Interaction with S6 ATPase, and Suppress Gankyrin/MDM2-Dependent Ubiquitination of p53.
    Chapman AM; McNaughton BR
    ACS Chem Biol; 2015 Aug; 10(8):1880-6. PubMed ID: 25955581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stabilization of protein-protein interactions by small molecules.
    Giordanetto F; Schäfer A; Ottmann C
    Drug Discov Today; 2014 Nov; 19(11):1812-1821. PubMed ID: 25173701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of SCY45, a Natural Small-Molecule MDM2-p53 Interaction Inhibitor.
    Gong H; An J; Dong Q; Li J; Yang W; Sun W; Su Z; Zhang S
    Chem Biodivers; 2019 Jun; 16(6):e1900081. PubMed ID: 30989812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
    Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Study: discovery of inhibitors of the MDM2-p53 protein-protein interaction.
    Liu L; Bernard D; Wang S
    Methods Mol Biol; 2015; 1278():567-85. PubMed ID: 25859977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
    Malaguarnera R; Vella V; Pandini G; Sanfilippo M; Pezzino V; Vigneri R; Frasca F
    Mol Cancer Res; 2008 Jan; 6(1):64-77. PubMed ID: 18234963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.